“…Surveillance endoscopy among individuals with Barrett's esophagus to identify those who would benefit from endoscopic or surgical treatment continues to be based on a failed premise; specifically, limiting screening to individuals with symptomatic reflux, while enriching the sample for Barrett's esophagus, excludes a large proportion of individuals who develop esophageal adenocarcinoma. 1 Current guidelines from many gastroenterology societies recommend endoscopy every 3 to 5 years using high-resolution white-light plus enhanced imaging (chromoendoscopy) to obtain targeted biopsies from any mucosal abnormalities in addition to random 4-quadrant biopsies taken every 1 to 2 cm along the length of Barrett's esophagus. 2 Several facts minimize the effectiveness of this strategy: screening is performed in a minority of eligible individuals 3 ; screening fails to detect the majority of individuals who develop esophageal adenocarcinoma 4 ; adherence to the recommended biopsy protocol is poor 5 ; there is discordance between pathologist's interpretation of histopathology 6 ; and individuals at high risk of esophageal adenocarcinoma also have high mortality from other diseases.…”